SeekingAlpha · Aug 7, 2026
HQH: After Biotech's Breakout Year, This Healthcare CEF Still Trades Below NAV; Buy
Abrdn Healthcare Investors biotech CEF: 6.4% NAV discount, 56% NAV gain, 12% gain-funded payout, key risks. Read my analysis here on HQH.
TE
NASDAQ · TECX
Tectonic Therapeutic, Inc.
Healthcare · Biotechnology
$37.63
Up+$1.58 (+4.38%)
Updated Aug 22, 2026, 1:41 PM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 364.22M
- P/E ratio
- -5.41
- Dividend yield
- 0.00%
- 52-week range
- $26.31 – $39.53
- Volume
- 188.56K
- Avg. volume
- 513.83K
Price performance
TECX price history
1M range · 21 trading sessions · Daily adjusted prices
TECX closed at $37.63 after 21 trading sessions, up 23.91% for the selected period.
- Last close
- $37.63
- Period change
- +23.91%
- Period low
- $27.92
- Period high
- $37.63
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $36.42 | $38.23 | $36.375 | $37.63 | 188.56K |
| Aug 20, 2026 | $36.51 | $37.225 | $35.68 | $36.05 | 196.85K |
| Aug 19, 2026 | $37.10 | $37.50 | $36.07 | $37.04 | 199.97K |
| Aug 18, 2026 | $33.79 | $37.195 | $33.50 | $36.61 | 453.32K |
| Aug 17, 2026 | $34.90 | $35.06 | $33.70 | $33.85 | 143.89K |
| Aug 14, 2026 | $33.63 | $35.025 | $33.32 | $34.91 | 84.24K |
| Aug 13, 2026 | $37.06 | $37.40 | $33.85 | $33.98 | 277.75K |
| Aug 12, 2026 | $31.89 | $37.30 | $31.89 | $36.83 | 665.62K |
| Aug 11, 2026 | $33.09 | $33.7448 | $31.70 | $31.87 | 162.59K |
| Aug 10, 2026 | $31.12 | $33.015 | $30.00 | $32.71 | 139.36K |
| Aug 7, 2026 | $30.79 | $31.84 | $30.45 | $30.98 | 271.65K |
| Aug 6, 2026 | $29.91 | $30.805 | $29.5125 | $30.22 | 91.97K |
| Aug 5, 2026 | $29.49 | $30.01 | $28.57 | $29.56 | 125.94K |
| Aug 4, 2026 | $28.27 | $29.51 | $27.805 | $29.17 | 145.91K |
| Aug 3, 2026 | $27.80 | $28.27 | $27.305 | $27.92 | 106.04K |
| Jul 31, 2026 | $28.47 | $28.599 | $27.24 | $28.03 | 253.09K |
| Jul 30, 2026 | $28.28 | $29.075 | $27.82 | $28.51 | 185.47K |
| Jul 29, 2026 | $29.83 | $30.4964 | $27.96 | $28.43 | 165.22K |
| Jul 28, 2026 | $30.78 | $30.78 | $29.39 | $29.80 | 146.35K |
| Jul 27, 2026 | $30.53 | $31.54 | $30.33 | $30.61 | 160.86K |
| Jul 24, 2026 | $31.61 | $31.73 | $30.245 | $30.37 | 99.11K |
Latest TECX news
The latest Smart Investors Daily articles mentioning TECX.
Stock researchCompany · Overview
TECX research
Overview
Company profile and research snapshot.
Company profile
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Wells Fargo | Overweight | — |
| May 26, 2026 | Raymond James | Strong Buy | — |
| Apr 14, 2026 | Stifel | Buy | — |
| Jan 8, 2026 | Truist Securities | Buy | — |
| Sep 3, 2025 | Oppenheimer | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Wells Fargo Maintains Overweight on Tectonic Therapeutic, Lowers Price Target to $93
Wells Fargo analyst Tiago Fauth maintains Tectonic Therapeutic (NASDAQ:TECX) with a Overweight and lowers the price target from $101 to $93.
Benzinga · Aug 6, 2026
Tectonic Therapeutic Q2 EPS $(1.18) Beats $(1.37) Estimate
Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.18) per share which beat the analyst consensus estimate of $(1.37) by 13.87 percent. This is a 10.28 percent decrease over losses of $(1.07) per share
Benzinga · May 26, 2026
Raymond James Upgrades Tectonic Therapeutic to Strong Buy, Raises Price Target to $81
Raymond James analyst Michael Freeman upgrades Tectonic Therapeutic (NASDAQ:TECX) from Outperform to Strong Buy and raises the price target from $76 to $81.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
